179 related articles for article (PubMed ID: 22884144)
1. Efficacy and safety of neoadjuvant chemotherapy with modified FOLFOX7 regimen on the treatment of advanced gastric cancer.
Zhang J; Chen RX; Zhang J; Cai J; Meng H; Wu GC; Zhang ZT; Wang Y; Wang KL
Chin Med J (Engl); 2012 Jun; 125(12):2144-50. PubMed ID: 22884144
[TBL] [Abstract][Full Text] [Related]
2. [A prospective study of FOLFOX7 scheme as neoadjuvant chemotherapy for stage III gastric adenocarcinoma].
Liu YH
Zhonghua Wai Ke Za Zhi; 2009 Sep; 47(17):1305-8. PubMed ID: 20092724
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A
Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914
[TBL] [Abstract][Full Text] [Related]
4. Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer.
Baek YH; Choi SR; Jang JS; Roh MH; Lee JH; Won JJ; Lee CM
Hepatogastroenterology; 2011; 58(105):251-6. PubMed ID: 21510324
[TBL] [Abstract][Full Text] [Related]
5. A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer.
Tai Q; Shao H; Liu Y; Li E; Zhao R
J BUON; 2019; 24(5):2006-2012. PubMed ID: 31786868
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of 56 patients with advanced gastric cancer treated with combination of intravenous and intra-arterial intensified neoadjuvant chemotherapy.
Li GL; Liu K; Bao Y; Cao JM; Xu J; Wang XL; Wu B; Li JS
Chin Med J (Engl); 2012 Mar; 125(5):780-5. PubMed ID: 22490574
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
[TBL] [Abstract][Full Text] [Related]
8. [Value of normalization window of tumor vasculature in neoadjuvant chemotherapy for patients with unresectable gastric cancer].
Zheng YB; Cao FY; Liu KJ; Gan HF; He XB; Tong SL
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Jan; 15(1):55-8. PubMed ID: 22287353
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy versus surgery alone for locally advanced gastric cancer: a retrospective comparative study.
Wang LB; Shen JG; Xu CY; Chen WJ; Song XY; Yuan XM
Hepatogastroenterology; 2008; 55(86-87):1895-8. PubMed ID: 19102417
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of the predictors to neoadjuvant chemotherapy in patients with advanced gastric cancer].
Qu JJ; Shi YR; Hao FY
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):276-80. PubMed ID: 23536352
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Abbrederis K; Bassermann F; Schuhmacher C; Voelter V; Busch R; Roethling N; Sendler A; Siewert JR; Peschel C; Lordick F
Ann Thorac Surg; 2006 Jul; 82(1):293-7. PubMed ID: 16798232
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
[TBL] [Abstract][Full Text] [Related]
15. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Lorenzen S; Blank S; Lordick F; Siewert JR; Ott K
Ann Surg Oncol; 2012 Jul; 19(7):2119-27. PubMed ID: 22395980
[TBL] [Abstract][Full Text] [Related]
16. Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer.
Ahn HS; Jeong SH; Son YG; Lee HJ; Im SA; Bang YJ; Kim HH; Yang HK
Br J Surg; 2014 Nov; 101(12):1560-5. PubMed ID: 25200278
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer.
Li ZY; Koh CE; Bu ZD; Wu AW; Zhang LH; Wu XJ; Wu Q; Zong XL; Ren H; Tang L; Zhang XP; Li JY; Hu Y; Shen L; Ji JF
J Surg Oncol; 2012 Jun; 105(8):793-9. PubMed ID: 22189752
[TBL] [Abstract][Full Text] [Related]
18. Complete pathologic response with combination oxaliplatin and 5-fluorouracil chemotherapy in an older patient with advanced gastric cancer.
Amini A; Sanati H
Anticancer Drugs; 2011 Nov; 22(10):1024-6. PubMed ID: 21822120
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer.
Tsuburaya A; Nagata N; Cho H; Hirabayashi N; Kobayashi M; Kojima H; Munakata Y; Fukushima R; Kameda Y; Shimoda T; Oba K; Sakamoto J
Cancer Chemother Pharmacol; 2013 May; 71(5):1309-14. PubMed ID: 23463482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
